Rare bullous pemphigoid during PD-1 inhibitor therapy: A case report
Immunotherapy is an important treatment modality in cancer, but it can also cause adverse reactions, with skin toxicity being the most common. The increasing number of immune checkpoint in hibitors being used in the clinic will inevitably cause an increase in the rate of adverse skin reactions that markedly affect the patient’s quality of life. A 58-year-old patient with intrahepatic cholangio carcinoma developed bullous pemphigoid (BP) nearly a year after using immune checkpoint inhibitors, which is different from what has been reported in the literature within two weeks of treatment. Pathologically, the skin biopsy diagnosis was epidermal hyper plasia and focal sub-epidermal pustule formation, consistent with drug-induced dermatitis.
Rare bullous pemphigoid during PD-1 inhibitor therapy: A case report Read More »